Health

Bringing it home: SA is leading the charge to make anti-HIV jab for Africa 

South Africa’s National Aids Council, Sanac, has asked local drug companies to submit applications by April 7 to make generic versions of an anti-HIV jab that could end Aids by 2043 in the country. The original version of the once-every-six-months shot, known as lenacapavir, is produced by the US pharmaceutical company, Gilead Sciences. Sanac will submit a shortlist of successful applicants, who met the requirements of the Council’s expression of interest call, to Gilead by July.

No need for pad panic, experts say

Together with sanitary pad and pantyliner manufacturers, specialists say there is no evidence of a health risk even though a UFS study has found they contain hormone-disrupting chemicals